Search results (1331)
« Back to PublicationsRadiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment.
Mehta S. et al, (2016), EBioMedicine, 10, 109 - 116
Timing of onset and resolution of adverse events in patients with unresectable stage IIIB-IVM1a melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM
Andtbacka R. et al, (2016), MELANOMA RESEARCH, 26, E36 - E37
PREDICTING PATHOLOGICAL RESPONSE OF ESOPHAGEAL CANCER TO NEOADJUVANT CHEMOTHERAPY: THE IMPLICATIONS OF METABOLIC NODAL RESPONSE FOR PERSONALISED THERAPY
Findlay JM. et al, (2016), Journal of Nuclear Medicine
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome
Roberts C. et al, (2016), British Journal of Haematology
Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.
Quek L. et al, (2016), The Journal of experimental medicine, 213, 1513 - 1535
Delayed oral toxicity from BRAF-targeted therapy
Lloyd-Lavery A. et al, (2016), BRITISH JOURNAL OF DERMATOLOGY, 175, 24 - 24
Durable response rates with talimogene laherparepvec or granulocyte-macrophage colony-stimulating factor are associated with additional clinical benefits in patients with stage IIIB-IVM1a melanoma in the OPTiM trial
Harrington K. et al, (2016), BRITISH JOURNAL OF DERMATOLOGY, 175, 73 - 73
Erratum to: Genetic Biomarkers of Barrett's Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis.
Findlay JM. et al, (2016), Dig Dis Sci, 61
Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.
Middleton MR. et al, (2016), Cancer Med, 5, 1436 - 1443
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
Mateo J. et al, (2016), Targeted oncology, 11, 401 - 415
Distinct myeloid progenitor differentiation pathways identified through single cell RNA sequencing
Nerlov C. et al, (2016), Nature Immunology
Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.
Eyre TA. et al, (2016), Br J Haematol, 173, 896 - 904
RUXOLITINIB COMPARED WITH BEST AVAILABLE THERAPY FOR ESSENTIAL THROMBOCYTHAEMIA PATIENTS RESISTANT OR INTOLERANT TO HYDROXYCARBAMIDE IN MAJIC - AN INVESTIGATOR LEAD RANDOMIZED TRIAL
Harrison C. et al, (2016), HAEMATOLOGICA, 101, 97 - 97
SINGLE-CELL PROFILING OF HUMAN MEGAKARYOCYTE-ERYTHROID PROGENITORS IDENTIFIES DISTINCT MEGAKARYOCYTE AND ERYTHROID DIFFERENTIATION PATHWAYS
Psaila B. et al, (2016), HAEMATOLOGICA, 101, 21 - 21
A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D.
Armand P. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34
Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) A phase 2 study.
Younes A. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34
Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792).
Plummer ER. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34
Real-world overall survival in advanced melanoma from the IMAGE study.
Middleton MR. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34
Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma
Middleton MR. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
Mateo J. et al, (2016), Targeted Oncology